ImmunoGen cancer treatment application gets another chance

ImmunoGen has been given the go-ahead to revive its patent application for a cancer treatment dosage following a Federal Circuit ruling on Friday.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Federal Circuit dismisses Phigenix patent appeal in ImmunoGen case

10 January 2017 Pharmaceutical research company Phigenix lost an appeal at the US Court of Appeals for the Federal Circuit yesterday, after the court found that the company lacked standing in a patent case against ImmunoGen.

Americas

Takeda signs deal with ImmunoGen to develop cancer drugs

25 March 2015 Massachusetts-based biotechnology company ImmunoGen has granted pharmaceutical company Takeda exclusive rights to use its antibody-drug conjugate technology to develop and commercialise cancer drugs.